| | | |
Mesothelioma |
NCT05380713 21-6216 | ......SMARTEST Trial...... | Dr. Marc de Perrot | Mesothelioma |
NCT06097728 D7988C00001, 2023-503231-17-00,2023-000067-32 | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Dr. Penelope Bradbury | Mesothelioma |
Multiple Sites |
NCT05789082 BO44426, 2022-003048-28,2023-507171-22-00 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Dr. Adrian Sacher | Multiple Sites |
NCT05094336 20210023, 2023-504363-17 | A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Dr. Adrian Sacher | Multiple Sites |
NCT05067283 1084-001, MK-1084-001,jRCT2041220034,2022-501563-40-00,U1111-1281-2482 | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Dr. Adrian Sacher | Multiple Sites |
NCT06333951 20230167 | AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Dr. Adrian Sacher | Multiple Sites |
NCT04534413 20-5565 | Ex-Vivo COF Study for Lung Cancer Observation | Dr. Kazuhiro Yasufuku | Multiple Sites |
NCT04782752 20-5902 | Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination | Dr. Marc de Perrot | Multiple Sites |
NCT03356743 16-6177 | Spectrum Analysis in Ex-vivo Human Lungs | Dr. Kazuhiro Yasufuku | Multiple Sites |
NCT03349307 16-6083 | Thin-EBUS in Ex-vivo Human Lungs | Dr. Kazuhiro Yasufuku | Multiple Sites |
Non Small Cell Lung Cancer (NSCLC) |
NCT05221840 D9078C00001, 2023-503999-24-00,2021-004346-37 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Dr. Frances Shepherd | Non Small Cell Lung Cancer (NSCLC) |
NCT05975073 20220127 | A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT06497556 BO45217, 2024-510908-37-00 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT06077760 V940-002, 2023-504923-20-00,U1111-1290-3969,jRCT2061240063,PHRR240705-007252 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Dr. Marc de Perrot | Non Small Cell Lung Cancer (NSCLC) |
NCT05118789 NVL-520-01 | A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Dr. Geoffrey Liu | Non Small Cell Lung Cancer (NSCLC) |
NCT04449874 GO42144, 2020-000084-22,2023-506311-18-00 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT06417814 D516KC00001, 2024-511362-37-00 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
NCT05048797 D967SC00001, 2023-503674-20-00,2021-000634-33 | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Dr. Penelope Bradbury | Non Small Cell Lung Cancer (NSCLC) |
NCT06452277 22615, 2024-511319-91-00 | A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
NCT04614103 IOV-LUN-202, 2020-003629-45,2024-510778-26-00 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |